1[1]Karnell R, Kagedal B, Lindholm C, et al. The value of cysteinyldopa in the follow-up of disseminated malignant melanoma. Melanoma-Res.2000, 10(4):363 - 9
2[2]Pu LL, Cruse CW, Wells KE, et al. Lymphatic mapping and sentinel lymph node biopsy in patients with melanoma of the lower extremity. PlastReconstr-Surg. 1999,104(4):964 - 9
3[3]Sersa G, Stabuc B, Cemazar M, et al. Electrochemotherapy with cisplatin:Clinical experience in malignant melanoma patients. Clin-CancerRes.2000,6(3) :863 - 7
4[4]Enk AH, Nashan D, Rubben A, et al. High dose inhalation interleukin-2therapy for lung metastases in patients with malignant melanoma. Cancer,2000,88(9): 2042 - 6
5[5]Savas B,Arslan G,Gelen T,et al. Multidrug resistant malignant melanoma with intracranial metastasis responding to immunotherapy. AnticancerRes,1999,19(5C): 4413 - 20
6[6]Ascierto PA,Palmieri G,Parasole R,et al.3-year treatment with recombinant interferon-alpha as adjuvant therapy of cutaneous malignant melanoma. Int-J-Mol-Med, 1999,3 (3): 303 - 6
7[7]Grimm EA, Smid CM, Lee JJ, et al. Unexpected cytokines in serum of malignant melanoma patients during sequential biochemotherapy. Clin-Cancer-Res, 2000,6(10): 3895 - 903
8[8]McClay EF, McClay ME, Monroe L, et al. The effect of tamoxifen and cisplatin on the isease-free and overall survival of patients with high risk malignant melanoma. Br-J -Cancer, 2000,83 (1): 16 - 21
9[9]Yamazaki N, Yamamoto A, Wada T, et al. Dacarbazine, nimustine hydrochloride, cisplatin and tamoxifen combination chemotherapy for advanced malignant melanoma. J-Dermatol, 1999,26 (8): 489 - 93
10[10]Graham MV. Hypofractioaated radiation therapy in the modern era. Rays,1999,24(3): 400 - 5
10Mesnil M, Yamasaki H. Bystander effect in herpes simplex virusthymidine kinase/ganciclovir cancer gene therapy: role of gapjunctional intercellular communication [ Jl. Cancer Res, 2000, 60 (15): 3989.
